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Introduction 
Diabetes mellitus is a chronic disease, associated with 
both micro- and macrovascular complications. Previous 
studies have shown that while the degree of glycaemic 
control [as measured by glycated haemoglobin (HbA1c)] is 
significantly associated with microvascular complications, 
it has less of an effect on macrovascular complications.1 
Most deaths in subjects with type 2 diabetes occur as a 
result of macrovascular (predominantly cardiovascular) 
disease.2 Therefore, focusing only on glycaemic control may 
impact less on mortality than on morbidity. Comprehensive 
management of patients with type 2 diabetes is needed, with 
emphasis on the management of all risk factors associated 
with the development of diabetes complications.
Macrovascular complications can be reduced with optimal 
control of blood pressure (BP) and lipid levels as well as 
by addressing other risk factors, such as reduction of body 
mass index (BMI) and cessation of cigarette smoking.3
Evidence-based guidelines are available to assist clinicians 
to manage patients in the most cost-effective and 
efficient manner. Many clinicians are either unaware of 
the existence of these guidelines or simply do not follow 
them. A number of countries, including South Africa, have 
developed guidelines, based on available evidence, to 
assist clinicians in the long-term management of patients 
with type 2 diabetes. However, there is a paucity of literature 
on adherence to diabetes management guidelines in South 
Africa. 
This motivated the current study to assess the efficacy 
of clinical management of subjects with type 2 diabetes 
attending the Medical Outpatients Department (MOD) of 
Addington Hospital, Durban, South Africa, and to establish 
whether the introduction of a diabetes monitoring and 
management protocol had had any effect on the metabolic 
and nonmetabolic control of these patients.
Abstract 
Background: A comprehensive approach to the control of type 2 diabetes is required to reduce mortality and morbidity. 
To improve diabetes management, in 2005 a protocol for the monitoring and management of type 2 diabetes, aligned to 
the 2003 Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) guidelines, was introduced at 
Addington Hospital Medical Outpatients Department, Durban, South Africa. 
Method: Data were collected from 120 randomly selected patients with type 2 diabetes. The number of glycated haemoglobin 
(HbA1c) and lipid estimations, blood pressure (BP) measurements and body mass indices (BMIs) recorded in 2005 was 
compared with those recorded in 2008 and 2009. The mean levels of these parameters and the number of patients reaching 
goal in 2008 were compared with the figures for 2009.
Results: In 2005, 18.8% of patients had HbA1c levels measured compared with 82.9% in 2009 (P < 0.01). The mean HbA1c 
was 6.9% (± 1.9) in 2008 and 6.4% (± 2.0) in 2009 (P = 0.1). BP and BMI was measured in over 93% of patients in 2005, 
2008 and 2009. BP goals were attained by 21% of patients in 2008 and 30% in 2009 (P = 0.65). The mean BMI in 2008 
was 29.4 kg/m2 (24% achieved goal), and in 2009 it was 28.6kg/m2 (29% achieved goal; P = 0.267). Lipid estimations rose 
significantly from 26% in 2005 to 73% in 2009 (P < 0.01). There was no improvement in the number of patients reaching 
target lipid levels between 2008 and 2009.
Conclusion: The monitoring protocol improved adherence to the SEMDSA 2003 guidelines from 2005 to 2009. Overall 
glycaemic control was within target, but attainment of most nonglycaemic goals was suboptimal and did not improve over 
the study period. 
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Addington Hospital MOD is a chronic medical clinic where 
stable medical patients are monitored and reviewed every 
six months and treatment is prescribed. Approximately 
30% of the 18 000 chronic patients seen annually at the 
MOD have diabetes mellitus. In September 2005, a protocol 
for the monitoring of patients with type 2 diabetes was 
introduced, based on the 2003 guidelines of the Society for 
Endocrinology, Metabolism and Diabetes of South Africa 
(SEMDSA). This report is an analysis of the effect of the 
introduction and implementation of the monitoring protocol 
at Addington Hospital MOD, comparing 2008 to 2009. The 
aim of the study was to determine the effect of the protocol 
on changes in HbA1c, lipid levels, BP, anthropometric 
parameters as well as the level of compliance of clinic staff 
in adherence to the guidelines, from 2008 to 2009. 
Method
This was an observational, analytic retrospective study. 
A sample size of 120 was calculated to give 73 pairs of 
results, which achieved the necessary power (80%), using 
a two-sided one-sample t-test. Using a random numbers 
table, 120 subjects who had been patients at the clinic 
since 2005 when the protocol for diabetic care was first 
introduced were selected. 
The protocol recommended, in accordance with the 2003 
SEMDSA guidelines, that at each six-monthly visit patients 
should have their BP and weight measured, BMI calculated 
and serum creatinine and HbA1c estimations performed. 
A fasting lipid profile should be performed either every six 
months or annually, depending on whether lipid levels were 
normal or elevated. The clinic doctors were given in-service 
training and instruction regarding the implementation of the 
protocol at the end of August 2005, when it was introduced. 
In 2007, following a routine notes audit, it was noted that 
investigations were not being performed and so the doctors 
were again “in-service trained” and the importance of 
following the protocol was stressed.
Following re-emphasis in 2007, data recorded in 2008 was 
compared to data recorded in 2009. Data was extracted 
from each subject’s clinical record. Laboratory results not 
recorded by the attending medical officer were obtained by 
searching the laboratory databases of Inkosi Albert Luthuli 
Central Hospital (IALCH, the reference laboratory) and 
Addington Hospital. 
The following data were collected from each patient file and 
recorded on a Microsoft Excel® spreadsheet:
•	 HbA1c
•	 Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP)
•	 Lipids: total cholesterol, low-density lipoprotein (LDL) 
cholesterol, high-density lipoprotein (HDL) cholesterol 
and triglycerides
•	 BMI, derived from the recorded height and weight and 
calculated as weight (kg) divided by height squared (m2)
Compliance with the protocol was judged by the number of 
HbA1c estimations performed in each year, as well as by the 
number of subjects in whom BMI and BP were measured 
and lipid profiles were performed. 
Clinical measurements
Body weight and height were measured using electronic 
scales with height measuring tape. The original (first-
measured) height was used throughout, to counter any 
variation in observer readings. Patients in wheelchairs or 
those who were unable to stand unaided were not measured.
Welch Allyn® electronic measuring machines were used to 
measure BP. These machines meet or exceed the SP10: 
1992 Association of Medical Instrumentation standard 
(± 5 mmHg mean error, 8 mmHg standard deviation).
Laboratory measurements
HbA1c was measured using an ion-exchange high-
performance liquid chromatography (HPLC) with a 
coefficient of variation (CV) of 1.15% (IALCH laboratory).
Lipid levels: Subjects were asked to fast from 22h00 the 
night before, and blood was taken at 08h00. Lipids were 
measured on the Beckman Coulter UniCel® DxC Synchron® 
800 analyser (DXC800) in the Addington Hospital laboratory. 
For total cholesterol, the cholesterol esterase method was 
used with a CV of 4.5 %. HDL cholesterol was measured 
employing the direct homogenous method using cholesterol 
esterase and cholesterol oxidase with a CV of 4.5%. 
Triglyceride levels were assessed by the glycerol phosphate 
oxidase method with a CV of 4.5 %. For LDL cholesterol the 
Friedewald equation [total cholesterol - (HDL cholesterol + 
triglyceride / 2.2] was used (Addington hospital laboratory).
Bias was eliminated by the inclusion of all suitable subjects. 
There were three patients whose files could not be located 
and two patients whose files were incomplete. These 
patients were included. 
Statistical analysis
Data was recorded as mean ± standard deviation. 
McNemar’s paired t-test was used to compare the means 
of the parameters measured in 2008 with the corresponding 
parameters in 2009. Chi-square test was used to compare 
the percentage of subjects attaining preset goals in 2008 
and in 2009. The level of significance was set at 0.05. No 
confounders were considered or measured.
Ethics approval
Ethics approval was obtained from the Postgraduate 
Committee at the Nelson R Mandela School of Medicine, 
the Biomedical Research Ethics Committee of the University 
of KwaZulu-Natal (reference number EXP003/06), the Ethics 
Committee at Addington Hospital and the Provincial Health 
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Research Committee, and permission to do the study at 
Addington Hospital was obtained from the acting medical 
manager.
Results
Of the 120 randomly selected patients, 117 files were 
located. Of these, 115 files were complete. In the case of two 
files, the data for 2005 was missing but the later data (2008 
and 2009) was available. These patients were included, as 
the significant data required was that of 2008 and 2009. The 
study group comprised 37 men and 82 women. Ages were 
not recorded.
Table I shows the number of tests performed for each 
measured parameter. The number of investigations 
performed in 2005 (before the introduction of the protocol) 
is included as a comparison with what was done in 2008 
and 2009, after the protocol was re-emphasised. Very few 
HbA1c (18.8%) estimations were performed in 2005, but 
there was a significant improvement in 2008 (74.3%) and 
2009 (82.9%, P < 0.01).
There was no significant difference in the number of BP 
measurements performed between any of the years (2008 
vs. 2009, P = 1.0).
In 2005, only 5% of patients had fasting lipid levels 
requested with 21% of the subjects having had total 
cholesterol levels measured only. In 2008, 35% of subjects 
had full lipid profiles, with another 36% having had total 
cholesterol levels measured only. In 2009, 51% of patients 
had fasting lipid levels estimated, with a further 22% having 
had total cholesterol levels measured only. There was a 
significant improvement in the number of fasting lipid profile 
estimations between 2005 and 2009 (P < 0.01) and between 
2008 and 2009 (P < 0.01).
Table II shows the metabolic and nonmetabolic parameters 
recorded in the study group in 2008 and 2009. Over the study 
period, no significant change was observed in HbA1c, SBP, 
DBP or BMI values. Total cholesterol and LDL cholesterol 
remained virtually unchanged, while triglycerides and HDL 
cholesterol deteriorated slightly. 
The mean HbA1c in 2005 was 8.6 (±1.9) %, but the mean 
HbA1c for both 2008 and 2009 was within the recommended 
goal level (< 7%). The reduction of 0.4% in HbA1c levels 
between 2008 and 2009 was not statistically significant 
(p = 0.1). Nonsignificant improvement in SBP, DBP, total 
cholesterol, LDL cholesterol and BMI occurred from 2008 
to 2009 while there was a nonsignificant deterioration in 
triglycerides and HDL cholesterol.
Table III shows the number of subjects reaching target levels. 
The number of subjects reaching the goal for HbA1c did not 
improve significantly between 2008 and 2009 (P = 0.307). In 
2008 only 20% of subjects reached the SBP goal levels while 
in 2009, 31% did. This trend did not, however, reach 
significance (P = 0.065). There was no significant 
improvement in subjects reaching goal DBP 
(P = 0.59). Lipid control deteriorated between 2008 
and 2009. There was no significant improvement 
in subjects reaching goal for total cholesterol 
(P = 0.227) while the number for triglycerides 
(P = 0.125), HDL cholesterol (P = 0.063) and LDL 
cholesterol (P = 1.0) all deteriorated.
The increase in subjects reaching BMI levels was 
not significant.
Table III: Number of patients (%) reaching the SEMDSA 
2003 goals
Parameter 2008 n (%) 2009 n (%) P
HbA1c 51 (59) 69 (71) 0.307
SBP 23 (20) 35 (31) 0.065
DBP 61 (53) 65 (57) 0.590
Total cholesterol 33 (40) 41 (44) 0.227
Triglycerides 19 (46) 26 (38) 0.125
HDL cholesterol 15 (38) 13 (19) 0.063
LDL cholesterol 24 (60) 29 (45) 1.0
Body mass index 27 (24) 33 (29) 0.267
Table I: Number of tests performed in 2005 (before the introduction of the protocol), 
compared with 2008 and 2009 (after the introduction)
2005 n (%) 2008 n (%) 2009 n (%) P value*
HbA1c 22 (18.8) 87 (74.3) 97 (82.9) < 0.01
Blood pressure measurement 109 (93.1) 115 (98.3) 114 (97.4) 1.0
Total cholesterol levels only 25 (21) 42 (36) 26 (22) 0.71
Fasting lipid profiles 6 (5) 41 (35) 68 (51) < 0.01
Body mass index 108 (92) 108 (92) 110 (94) 1.0





2008* 2009* P value
HbA1c (%) < 7 6.9 (2.0) 6.4 (1.9) 0.1
SBP (mmHg) < 130 143 (20) 141 (20) 0.065
DBP (mmHg) < 80 79 (11) 78 (10) 0.590
Total cholesterol (mmol/l) < 5.0 5.1 (1.0) 5.0 (1.0) 0.227
Triglyceride (mmol/l) < 1.5 1.7 (0.8) 2.0 (1.2) 0.125
HDL cholesterol (mmol/l) ≥ 1.2 1.15 (0.35) 1.03 (0.31) 0.063
LDL cholesterol (mmol/l) < 3 3.06 (0.96) 3.05 (1.05) 1.0
Body mass index (kg/m2) < 25 29.4 (9.7) 28.6 (9.74) 0.267
* Data expressed as mean (± standard deviation)
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Discussion
A number of landmark clinical studies have shown that 
good glycaemic control in subjects with type 2 diabetes 
reduces microvascular complications and, to a lesser 
extent, macrovascular complications. More recently, 
glycaemic control has been shown to have a beneficial 
effect on long-term macrovascular complications if good 
control is achieved from the time of diagnosis.4 Despite this 
information being widely known, attainment of metabolic 
and nonmetabolic targets is often not achieved or sustained. 
This study aimed to address this important issue through the 
implementation of a specific guideline protocol in a group of 
subjects with type 2 diabetes, managed at a primary care 
level. Each medical practitioner at the site was encouraged 
to implement the protocol which was based on the existing 
SEMDSA guidelines. The implementation of the guideline 
protocol was reinforced through in-service training, and the 
study sought to measure the efficacy of this intervention, 
both on metabolic and nonmetabolic parameters. 
Addington Hospital MOD caters for a wide range of general 
medical conditions, including type 2 diabetes. Adherence 
to the guidelines for the management of type 2 diabetes 
at a primary health care level put out by SEMDSA in 2003 
(that every affected subject requires determination of HbA1c 
at least six-monthly) was shown to be grossly suboptimal 
when the 2005 statistics were evaluated.
The current data showed that the number of HbA1c 
estimations rose significantly from 2005 (18.8%) to 2008 
(74.3%) and to 2009 (82.9%, P = 0.01), suggesting an 
improvement in the level of compliance with the guidelines 
by the doctors. Notwithstanding this improvement, 17.1% 
of patients still did not have a single HbA1c level measured 
in 2005, 2008 and 2009. The present study showed that in 
2008, 59% of patients were at the SEMDSA target for HbA1c 
and by 2009 this had risen to 72%. However, this difference 
was not significant (P = 0.307). Between 2008 and 2009, the 
mean HbA1c level fell from 6.9% to 6.4%. These observations 
are difficult to explain, given the preponderance of literature 
showing the difficulty in attaining and sustaining HbA1c 
levels. One feature of the study population that may have 
influenced the HbA1c results was the fact that the majority 
of subjects had been attending the clinic since 2005 and 
were still attending in 2009, indicating a good degree of 
compliance with clinic attendance and, possibly, also with 
adherence to treatment regimens. In addition, it is usual for 
patients with poor glycaemic control to be referred from 
Addington Hospital MOD to a higher level of expertise for 
assistance with ongoing care, and thus the remaining clinic 
attendees were overall more stable, with good glycaemic 
control. 
The study showed that the overall results for HbA1c were 
good with 82.9% of patients having HbA1c estimations 
performed and 72% of patients at target goal. There was 
significant improvement in HbA1c measurement between 
2005 and 2008/2009, and this suggests adherence to 
recommended practice guidelines by the attendant medical 
officer staff complement and a positive outcome to the 
implementation of the protocol for the management of type 
2 diabetes in Addington Hospital MOD.
Blood pressures are recorded routinely in patients attending 
Addington Hospital MOD, and so the high levels of 
compliance achieved for this parameter (in excess of 90%) 
are expected. There is extensive evidence that targeted 
antihypertensive treatment is important for cardiovascular 
risk reduction in patients with type 2 diabetes, and therefore 
every effort should be made to reach goal levels.5 Control 
of SBP has been suggested to be a more important 
cardiovascular risk-reduction factor than control of DBP, 
except in patients younger than 50 years, but SBP is more 
difficult to control.6 As most patients (especially those 
younger than 50 years) with hypertension will reach the 
DBP goal once SBP is at goal, the primary focus should 
be on achieving the SBP goal.7 However, in the present 
study only 30% were in the target range for SBP. There 
are recommendations that patients adhering to full doses 
of an appropriate three-drug regimen and who are not 
reaching goal BP levels should be referred to a hypertension 
specialist.7 The present study did not collect information on 
anti-hypertensive therapy and it is not possible to define the 
reasons for the lack of uniform attainment of BP goals. This 
finding nevertheless highlights an important shortcoming in 
the management of these patients that will require further 
attention in order that the overall degree of blood pressure 
control is improved. 
Lipids play an important part in cardiovascular and stroke 
risk. Patients with type 2 diabetes commonly present with 
atherogenic dyslipidaemia, characterised by elevated 
triglycerides, low plasma levels of HDL cholesterol and a 
preponderance of small dense LDL cholesterol particles, 
which increase the risk of atherogenesis even at normal 
LDL cholesterol concentrations.8 Therefore, it is important 
to attempt to reduce triglyceride and LDL cholesterol levels 
while elevating HDL cholesterol levels. There is extensive 
trial evidence that a reduction in lipid levels is important 
for lowering the cardiovascular risk in patients with type 2 
diabetes.9 The United Kingdom Prospective Diabetes Study 
(UKPDS 23) showed that a low HDL cholesterol level and an 
increase in LDL cholesterol levels predicted coronary heart 
disease to a greater extent than hyperglycaemia.10 For this 
reason, obtaining fasting lipid profiles is more relevant than 
obtaining a total cholesterol level.
In the present study, only 26% of patients had any form of 
lipid measurement performed in 2005 and of these only 5% 
were fasting lipid profiles. In 2008, 71% of the study group 
had lipid estimations performed, but only 35% were fasting 
lipid profiles. By 2009, 51% of patients had fasting lipid 
profiles performed although the total lipid tests remained 
constant at 73%. The improvement between 2005 and 2008 
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is significant (P = 0.01), as is the improvement between 
2008 and 2009 (P = 0.01), indicating improved compliance 
on the part of the doctors. 
For accurate results, patients need to fast for 10 hours prior 
to having a fasting lipid profile performed. Patients may 
forget to fast for the required time period, and this would 
limit the number of fasting lipid profiles that can actually 
be performed. At Addington Hospital MOD, total cholesterol 
estimation is ordered on patients who have forgotten to 
fast. The mean total cholesterol in 2009 was 5.0 mmol/l, 
but only 44% of patients achieved the SEMDSA goal. There 
was no significant improvement compared to the 40% who 
achieved goal in 2008 (P = 0.227). The results of the fasting 
lipid profile estimations were disappointing, with fewer 
patients reaching SEMDSA goal levels in 2009 than in 2008.
As with BP recording, height and weight are routinely 
measured at clinic visits, so the high levels of compliance 
achieved on these parameters (over 92%) were 
expected. The mean BMI fell from 29.4 kg/m2 in 2008 to 
28.6 kg/m2 in 2009, which is a small improvement. The 
number of patients who achieved goal BMI levels rose from 
24% in 2008 to 29% in 2009, but this is not statistically 
significant (P = 0.267). Despite this, these results provide 
some encouragement in light of the global struggle to 
contain the epidemic of obesity, from which South African 
populations are not exempt: in South Africa 30% of adult 
men and 55% of adult women are overweight.11 Weight 
gain is a major contributor to the increasing incidence 
of type 2 diabetes. Both are independent risk factors for 
the development of cardiovascular disease.12 Difficulties 
in achieving weight loss may be partly cultural, and it has 
been shown that few overweight black women consider 
themselves overweight and that thinness is associated with 
human immunodeficiency virus/acquired immunodeficiency 
syndrome (HIV/AIDS).13 A Cape Town study of 240 black 
girls showed that two-thirds perceived fatness as a sign 
of happiness and wealth.14 Three-quarters of the girls 
associated thinness with ill health, notably HIV/AIDS and 
tuberculosis.
For any weight-reducing program to work, it needs 
reasonable weight goals, healthy eating, adequate physical 
activity and behavioural change.13 Jackson et al. suggest 
that obesity cannot be dealt with at a diabetes clinic.15 At 
Addington Hospital MOD, obese patients are referred to the 
dieticians for weight control, but more effort needs to be 
made to motivate patients to lose weight.
Study limitations 
Information on the doctors was pooled. There may be 
considerable variation in the adherence to the protocol by 
different doctors. Unfortunately, patients did not always see 
the same doctor and may have been treated by different 
doctors at each visit. Only results that were recorded could 
be analysed. Information on lifestyle and advice to reduce 
weight may have been given but not recorded.
Conclusion and recommendations 
The introduction of a protocol does not ensure that doctors 
will adhere to the protocol, nor does it mean that goals will 
be met.
This study showed that with repeated emphasis the protocol 
was accepted and guidelines were followed in relation to 
the investigation performed, but although overall glycaemic 
control was within target, attainment of most nonglycaemic 
goals was suboptimal and did not improve over the study 
period. 
 The introduction of a guideline must be accompanied by 
in-depth education for the doctors concerned, as well as 
regular re-emphasis of the guideline. Only in this way will 
guidelines become accepted and implemented. Further 
studies are needed to determine why guidelines are not 
routinely followed and whether, with time, more patients in 
this study will achieve target goals.
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